New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.

[1]  J. Gut,et al.  Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies. , 2011, Journal of medicinal chemistry.

[2]  S. Neidle,et al.  C-11 diamino cryptolepine derivatives NSC748392, NSC748393, and NSC748394: anticancer profile and G-quadruplex stabilization. , 2010, Bioorganic & medicinal chemistry letters.

[3]  J. Lavrado,et al.  Indoloquinolines as scaffolds for drug discovery. , 2010, Current medicinal chemistry.

[4]  C. Chien,et al.  Novel indoloquinoline derivative, IQDMA, induces G(2)/M phase arrest and apoptosis in A549 cells through JNK/p38 MAPK signaling activation. , 2009, Life sciences.

[5]  L. Maes,et al.  Synthesis and antiplasmodial activity of aminoalkylamino-substituted neocryptolepine derivatives. , 2009, Journal of medicinal chemistry.

[6]  J. Gut,et al.  Cryptolepine analogues containing basic aminoalkyl side-chains at C-11: synthesis, antiplasmodial activity, and cytotoxicity. , 2008, Bioorganic & medicinal chemistry letters.

[7]  D. Duś,et al.  Biological evaluation of omega-(dialkylamino)alkyl derivatives of 6H-indolo[2,3-b]quinoline--novel cytotoxic DNA topoisomerase II inhibitors. , 2005, Anticancer research.

[8]  S. Croft,et al.  Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. , 2005, Journal of medicinal chemistry.

[9]  N. Garbett,et al.  Extending nature's leads: the anticancer agent ellipticine. , 2004, Current medicinal chemistry. Anti-cancer agents.

[10]  L. Kaczmarek,et al.  Synthesis of 6-substituted 6H-indolo[2,3-b]quinolines as novel cytotoxic agents and topoisomerase II inhibitors. , 2002, Acta poloniae pharmaceutica.

[11]  L. Kaczmarek,et al.  Synthesis, and cytotoxic activity of some novel indolo[2,3-b]quinoline derivatives: DNA topoisomerase II inhibitors. , 1999, Bioorganic & medicinal chemistry.

[12]  F. Pognan,et al.  Synthesis and structure-activity relationship of methyl-substituted indolo[2,3-b]quinolines: novel cytotoxic, DNA topoisomerase II inhibitors. , 1994, Journal of medicinal chemistry.

[13]  F. Pognan,et al.  A carboline derivative as a novel mammalian DNA topoisomerase II targeting agent. , 1992, Biochemical pharmacology.

[14]  Harker Wg,et al.  Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. , 1991 .

[15]  P. Meltzer,et al.  Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. , 1989, Cancer research.

[16]  S. Gabriel,et al.  Ueber eine Darstellungsweise der Phtalazine , 1897 .

[17]  R. Humeniuk,et al.  Cytotoxicity and cell cycle effects of novel indolo[2,3-b]quinoline derivatives. , 2003, Oncology research.

[18]  L. Kaczmarek,et al.  Biotransformation of azacarbazoles as a means of developing novel antineoplastic compounds , 1989 .

[19]  W. Peczyńska-Czoch,et al.  Cancerostatics, VI. Synthesis and Antineoplastic Properties of Some Benzo‐iso‐α‐carbolines , 1988 .

[20]  R. Robinson,et al.  LXXVI.—Harmine and harmaline. Part VII. A synthesis of apoharmine and of certain carboline and copyrine derivatives , 1924 .